Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $162,612,689 across 8 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-347068

Period
2026-06-30
Reported value
$163M
Holdings
8
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
JBIOreduced-534,037-$11.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-347068, largest first. % of portfolio is the value over $162,612,689, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 5,652,922 shares; 2025Q1: 5,652,922 shares; 2025Q2: 5,652,922 shares; 2025Q3: 5,652,922 shares; 2025Q4: 4,382,687 shares; 2026Q1: 3,180,780 shares; 2026Q2: 3,180,780 shares 3,180,780$77M47.34%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 12,166,109 shares; 2026Q2: 12,166,109 shares 12,166,109$29.8M18.33%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,525,820 shares; 2025Q3: 1,525,820 shares; 2025Q4: 1,525,820 shares; 2026Q1: 1,525,820 shares; 2026Q2: 991,783 shares 991,783$22M13.55%-534,037Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,656,888 shares; 2025Q4: 2,656,888 shares; 2026Q1: 2,656,888 shares; 2026Q2: 2,656,888 shares 2,656,888$15.1M9.28%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 918,163 shares; 2024Q4: 918,163 shares; 2025Q1: 918,163 shares; 2025Q2: 542,628 shares; 2025Q3: 542,628 shares; 2025Q4: 542,628 shares; 2026Q1: 542,628 shares; 2026Q2: 542,628 shares 542,628$8.89M5.47%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 498,558 shares; 2024Q4: 498,558 shares; 2025Q1: 498,558 shares; 2025Q2: 498,558 shares; 2025Q3: 148,831 shares; 2025Q4: 148,831 shares; 2026Q1: 148,831 shares; 2026Q2: 148,831 shares 148,831$8.12M4.99%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,007,704 shares; 2024Q4: 2,007,704 shares; 2025Q1: 2,007,704 shares; 2025Q2: 2,007,704 shares; 2025Q3: 2,007,704 shares; 2025Q4: 2,007,704 shares; 2026Q1: 2,007,704 shares; 2026Q2: 2,007,704 shares 2,007,704$1.39M0.86%0Timeline
Tempest Therapeutics, Inc.Tempest Therapeutics, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 3,507,055 shares; 2025Q1: not reported; 2025Q2: 269,772 shares; 2025Q3: 269,772 shares; 2025Q4: 269,772 shares; 2026Q1: 269,772 shares; 2026Q2: 269,772 shares 269,772$299K0.18%0

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-347068 base2026-08-12acceptance time not in the bulk data set